Jagsonpal Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 26, 2025, titled "Press Release for Unaudited Financial Results for the quarter ended June 30, 2025".
JAGSNPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Jagsonpal Pharmaceuticals posted strong Q1FY26 results with revenue rising 23.1% YoY to ₹756 Mn (up 29.1% QoQ from ₹586 Mn). Operating EBITDA grew 24.1% YoY to ₹157 Mn, with margins expanding 17 bps YoY to 20.8%. Net profit more than doubled to ₹108 Mn (up ~104% YoY from ₹53 Mn), with PAT margin expanding 562 bps to 14.3%. Gross margin improved 80 bps to 64.4%, reflecting strong brand equity and disciplined cost management. The company added ₹153 Mn of free cash during the quarter, taking its cash balance to ₹1,609 Mn as of June 30, 2025. Management also noted strengthening to #7 in the Gynae CVM rankings and guided for continued growth momentum in FY26.
Strong all-round performance with double-digit revenue growth, margin expansion, and profit doubling is positive for shareholders. The zero-debt status, growing cash pile (₹1,609 Mn), and high ROCE (23%) provide room for inorganic growth opportunities and likely support stock sentiment positively.